ROLE OF DIETARY SUPPLEMENTATION IN PREVENTING PROGRESSION OF AGE-RELATED MACULAR DEGENERATION

Age-related macular degeneration (AMD) is a chronic, progressive, degenerative eye disease affecting the central retina. It is the leading cause of blindness among individuals of 65 years and older. In the early stage patients have drusen and/or alterations of pigmentation in the macular region. This disease can progress to geographic atrophy and/or choroidal neovascularization. It has been shown that oxidative stress and hypoxia are important in the pathogenesis of AMD. Patients may gain some visual improvement with inhibitors of vascular endothelial growth factor, but complete restoration of visual function is achieved only in small cases. No effective therapies are known for atrophic AMD. Many large observational studies have shown that dietary antioxidant supplementation is beneficial in preventing the progression of AMD from early to late stages. The Age-Related Eye Disease Study (AREDS) demonstrated that daily oral supplementation with vitamins C (500 mg) and E (400 IU), beta carotene (15 mg), zinc (80 mg) and copper (2 mg) reduced the risk of progression to advanced AMD by 25% at 5 years. In primary analyses AREDS II failed to show further reduce of this risk by addition of lutein (10 mg) and zeaxanthin (2mg), or/and omega-3 long-chain polyunsaturated fatty acids [docosahexaenoic acid (350 mg DHA) and eicosapentaenoic acid 650 mg (EPA)] to the AREDS formulation. But there was no true placebo group. The simultaneous administration of beta carotene, lutein and zeaxanthin may suppress tissue level of the both laters because of competitive absorption of carotenoids. Subgroup analyses revealed that dietary supplementation with lutein, zeaxanthin and AREDS formulation without beta carotene may reduce the risk of progression to advanced AMD.The LUNA (Lutein nutrition effects measured by autofluorescence) study demonstrated that supplementation with lutein (12 mg), zeaxanthin (1 mg), vitamin C (120 mg), vitamin E (17,6 mg), zinc (10 mg), selenium (40 mg) resulted in a significant augmentation of macular pigment optical density (MPOD). This effect was more prominent in cases with initial low level of MPOD. The CARMA (Carotenoids in Age-Related Maculopathy) Study has shown that lutein (6 mg), zeaxanthin (0,3 mg), vitamin C (75 mg), vitamin E (7,5 mg), zinc (10 mg) and copper (0,2 mg) prevented progression from early to late stages of AMD. Early intervention is more effective in maintaining visual function.

1. Congdon N, O’Colmain B, Klaver CCW et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–85.

2. Evans JR, Fletcher AE, Wormald RPL. Causes of visual impairment in people aged 75 years and older in Britain: an add on study to the MRC Trial of Assessment and management of older people in the community. Br J Ophthalmol. 2004;88:365–70.

3. Friedman DS, O’Colmain BJ, Munoz B et al. Prevalence of age related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–72.

4. Lim LS, Mitchell P, Seddon JM, et al. Age related macular degeneration. Lancet. 2012;379:1728–38.

5. Hyman LG, Lilienfeld AH, Ferris FL et al. Senile macular degeneration: A case

6. control study. Am J Ophthalmol. 1983;118:213–22.

7. Leibowitz HM, Krueger DE, Maunder LR. The Framingham Eye Study. Surv Ophthalmol. 1980;24 (Suppl).

8. Klein Ronald, Peto Tunde, Bird Alan. The epidemiology of age related macular degeneration. Thomas G. Guilliams. The Standard Volume 2. No.1, 1999. Free Radicals, Antioxidants and Eye Diseases. Not As Incurable As We Once Thought.

9. Gass J. D. Stereoscopic atlas of macular diseases. St. Louis ets.: CV Mosby Co., 1977. – 411p.

10. Johnson EJ, Neuringer M, Russell RM, et al. Nutritional manipulation of primate retinas, III: Effects of lutein or zeaxanthin supplementation on adipose tissue and retina of xanthophyll free monkeys. Invest Ophthalmol Vis Sci. 2005;46:692–702.

11. Li B, Ahmed F, Bernstein PS. Studies on the singlet oxygen scavenging mechanism of human macular pigment. Arch Biochem Biophys.2010;504:56–60.

12. Beatty, S., Murray, I.J., Henson, D.B., et al. Macular pigment and risk for age related macular degeneration in subjects from a Northern European population. Investig. Ophthalmol. Vis. Sci. 2001;42 (2):439 446.

13. Bone, R.A., Landrum, J.T., Cains, A.. Optical density spectra of the macular pigment in vivo and in vitro. Vision Res. 1992;32 (1):105 110.

14. Sommerburg, O.G., Siems, W.G., Hurst, J.S., et al.. Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr. Eye Res. 1999;19(6):491 495.

15. Beatty S, Boulton ME, Henson DB. Macular pigment and age related macular degeneration. Br J Ophthalmol. 1999;83:867 77. 32.

16. Landrum JT, Bone RA, Kilburn MD. The macular pigment: A possible role in protection from age related macular degeneration. Adv. Pharm. 1997;38:537–56.

17. Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu Rev Nutr. 2003;23:171–201.

18. Malinow, M.R., Feeney Burns, L., Peterson, L.H., et al.. Diet related macular anomalies in monkeys. Investig. Ophthalmol. Vis. Sci. 1980;19(8):857 863.

19. Neuringer, M., Sandstrom, M.M., Johnson, E.J., Snodderly, D.M.. Nutri tional manipulation of primate retinas, I: effects of lutein or zeaxanthin supplements on serum and macular pigment in xanthophyll free rhesus monkeys. Investig. Ophthalmol. Vis. Sci. 2004;45(9):3234 3243.

20. Moeller SM, Parekh N, Tinker L, et al. Associations between intermediate age related macular degeneration and lutein and zeaxanthin in the carotenoids in age related eye disease study (CAREDS): ancillary study of the women’s healthinitiative. Arch Ophthalmol 2006;124:1151–62.

21. Tan JS, Wang JJ, Flood V, et al. Dietary antioxidants and the long term incidence of age related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2008;115:334–41.

22. Chong EW T, Wong TY, Kreis AJ et al. Dietary antioxidants and primary prevention of age related macular degeneration: Systematic review and meta analysis. BMJ. 2007.

23. Richer SP, Stiles W, Graham Hoffman K, et al. Randomized, double blind, placebo controlled study of zeaxanthin and visual function in patients with atrophic age related macular degeneration: the zeaxanthin and visual function study (ZVF) FDA IND #78, 973. Optometry. 2011;82:667–80.

24. Weigert G, Kaya S, Pemp B, et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:8174–8.

25. Sabour Pickett S, Beatty S, Connolly E, et al. Supplementation with three different macular carotenoid formulations in patients with early age related macular degeneration. Retina. 2014;34:1757–66.

26. Barlett HE, Eperjesi F. Effect of lutein and antioxidant dietary sup plementation on contrast sensitivity in age related macular disease: A randomized controlled trial. Eur J Clin Nutr. 2007 Sep;61(9):1121 7.

27. Massacesi KR, Faletra R, Gerosa F. The effect of oral supplementation of macular carotenoids (lutein and zeaxanthin) on the prevention of age related macular degeneration: A 18 months of follow up study. Ass Res Vis Ophthalmol. 2001;42:234.

28. Olmedilla B, Granado F, Blanco I et al. Lutein in patients with cataract and age related macular degeneration: A long term supplementation study. J Sci Food Agr. 2001;81:904–9.

29. Richer S. ARMD pilot (case series) environmental intervention data. J Am Optom Assoc. 1999;70:24–36.

30. Richer S, Stiles W, Statkute L. Double masked, placebo controlled, randomized trial of lutein and antioxidant supplementation in the in tervention of atrophic age related macular degeneration: The Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004;75:216–30.

31. Johnson, E.J., Hammond, B.R., Yeum, K.J.. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. Am. J. Clin. Nutr. 2000;71 (6):1555 1562.

32. Bone, R.A., Landrum, J.T., Dixon, Z., et al. Lutein and zeaxanthin in the eyes, serum and diet of human subjects. Exp. Eye Res. 2000;71(3):39 245.

33. Brady, W.E., Mares Perlman, J.A., Bowen, P., Stacewicz Sapuntzakis, M. Human serum carotenoid concentrations are related to physiologic and lifestyle factors. J. Nutr. 1996;126(1):129 137.

34. Ciulla, T.A., Curran Celantano, J., Cooper, D.A., et al.. Macular pigment optical density in a midwestern sample. Ophthalmology. 2001;108(4):730 737.

35. Hammond Jr., B.R., Ciulla, T.A., Snodderly, D.M.. Macular pigment density is reduced in obese subjects. Investig. Ophthalmol. Vis. Sci. 2002;43(1):47 50.

36. Rock, C.L., Thornquist, M.D., Neuhouser, M.L., et al.. Diet and lifestyle correlates of lutein in the blood and diet. J. Nutr. 2002;132 (3):525S 530S.

37. Kumari Neelam, Ruth E. Hogg, Michael R. Stevenson, et al. Carotenoids and co antioxidants in age related maculopathy: Design and Methods. Ophthalmic Epidemiology. 2008;15:389–401.

38. Trieschmann M., Beatty S., Nolan J M., Hense H W, et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental luteinand zeaxanthin: The LUNA study. Experimental Eye Research. 2007;84:718 728.

39. Berendschot, T.T., Goldbohm, R.A., Klopping, W.A., et al. Influence of lutein supplementation on macular pigment, assessed with two objective techniques. Investig. Ophthalmol. Vis. Sci. 2000;41(11):3322 3326.

40. Burke, J.D., Curran Celentano, J., Wenzel, A.J.. Diet and serum carotenoid concentrations affect macular pigment optical density in adults 45 years and older. J. Nutr. 2005;135 (5):1208 1214.

41. Curran Celentano, J., Hammond Jr., B.R., Ciulla, T.A., et al.. Relation between dietary intake, serum concentrations, and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Am. J. Clin. Nutr. 2001;74 (6):796 802.

42. Hammond Jr., B.R., Curran Celentano, J., Judd, S., et al.. Sex differences in macular pigment optical density: relation to plasma carotenoid concentrations and dietary patterns. Vision Res. 1996;36 (13):2001 2012.

43. Loughman J, Nolan JM, Howard AN, et al. The impact of macular pigment augmentation on visual performance using different carotenoid formulations. Invest Ophthalmol Vis Sci. 2012;53:7871–80.

44. Connolly EE, Beatty S, Thurnham DI, et al. Augmentation of macular pigment following supplementation with all three macular carotenoids: an exploratory study. Curr Eye Res. 2010;35:335–51.

45. Bernstein, P.S., Balashov, N.A., Tsong, E.D., Rando, R.R.. Retinal tubulin binds macular carotenoids. Investig. Ophthalmol. Vis. Sci. 1997;38(1):167 175.

46. Yemelyanov, A.Y., Katz, N.B., Bernstein, P.S., Ligand binding characterization of xanthophyll carotenoids to solubilized membrane proteins derived from human retina. Exp. Eye Res. 2001;72(4):381 392.

47. Bone, R.A., Landrum, J.T., Guerra, L.H., Ruiz, C.A.. Lutein and zeax anthin dietary supplements raise macular pigment density and serum con centrations of these carotenoids in humans. J. Nutr. 2003;133(4):992 998.

48. Age Related Eye Disease Study Group. A randomized, placebo controlled clinical trial of high dose supplementation with vitamins C and E, beta carotene, and zinc for age related macular degeneration and visual loss. Arch Ophthalmol. 2001;119:1417– 36.

49. Age Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. Lutein+Zeaxanthin and Omega 3 Fatty Acids for Age Related Macular Degeneration. JAMA. 2013;309(19):doi:10.1001/jama.2013.4997.

50. Wei LJ, Jin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989; 84(408):1065 1073.

51. Willett WC, Sampson L, Browne ML, et al. The use of a self administered questionnaire to assess diet four years in the past. Am J Epidemiol. 1988;127(1):188 199.

52. Yang Mu Huang, Hong Liang Dou, Fei Fei Huang, et al. Changes following supplementation with luteinand zeaxanthin in retinal function in eyes with early age related macular degeneration: a randomised, double blind, placebo controlled trial, BJO Online First, published on September 16, 2014 as 10.1136/bjophthalmol 2014 305503.